SCHEMBL23005229

SCHEMBL23005229

O=CN(c1ccc(NC(=O)CCl)c(Oc2ccccc2)n1)[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.41
RNF4 P78317 1/20 0.38
EPOR P19235 3/20 0.38
ALDH1A1 P00352 5/20 0.36
HTT P42858 2/20 0.36
POLB P06746 2/20 0.36
MITF O75030 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
BLM P54132 1/20 0.33
MAP2K7 O14733 1/20 0.33
LTA4H P09960 3/20 0.32
LMNA P02545 2/20 0.32
CYP1A2 P05177 1/20 0.32
GLA P06280 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C19 P33261 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23005204 0.88 FPR2 (0.38) FPR2ALDH1A1HTTMAPK1KMT2A
SCHEMBL23005147 0.84 ALDH1A1 (0.40) FPR2ALDH1A1HTTMITFKMT2A
SCHEMBL21494682 0.81 FPR2 (0.66) FPR2
SCHEMBL23005237 0.81 EPOR (0.42) FPR2EPORALDH1A1KMT2AMEN1
SCHEMBL23005144 0.81 FPR2 (0.39) FPR2ALDH1A1HTTKMT2AMEN1
SCHEMBL23005124 0.78 EPOR (0.40) EPORALDH1A1KMT2AMEN1CYP1A2
SCHEMBL23005235 0.74 FPR2 (0.67) FPR2RNF4ALDH1A1HTTPOLB
SCHEMBL23005232 0.74 FPR2 (0.67) FPR2RNF4ALDH1A1HTTPOLB
SCHEMBL21494601 0.70 FPR2 (0.65) FPR2
SCHEMBL23005245 0.68 CYP1A2 (0.34) FPR2EPORMAPK1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3781554-B1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) 2023-06-28 EP disclosed
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY MEDICINSK FORSKNING (SE) 2021-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY IL2, THPO, IL6 FPR2 435/4885RNF4 3964/4885EPOR 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.